跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FLUZONE HIGH-DOSE QUADRIVALENT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
FLUZONE HIGH-DOSE QUADRIVALENT
Authorized
STANDARD
FLUZONE HIGH-DOSE QUADRIVALENT
Sanofi Pasteur Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
42fb80a2f0bb8964
Company
Sanofi Pasteur Limited
Type
Standard
Approval Details
Approval Id
42fb80a2f0bb8964
Drug Approval Canada Name
FLUZONE HIGH-DOSE QUADRIVALENT
Product Name
FLUZONE HIGH-DOSE QUADRIVALENT
Status
Marketed
Status Date
2021-09-17
Original Market Date
2021-09-17
Din
02500523
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN
Atc Name
j 07 bb 02
Aig Number
0455410004
Company Name
Sanofi Pasteur Limited
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Company Detail Path
/organization/sanofi-pasteur-limited
Company Information
Pharmaceutical Company Name
Sanofi Pasteur Limited
Country Name
Canada
Province Name
Ontario
City Name
north york,ontario,country_ca
Address
1755 Steeles Ave W
Active Ingredients
HAEMAGGLUTININ-STRAIN A (H1N1)
60 MCG / 0.7 ML
HAEMAGGLUTININ-STRAIN A (H3N2)
60 MCG / 0.7 ML
HAEMAGGLUTININ-STRAIN B (VICTORIA)
60 MCG / 0.7 ML
HAEMAGGLUTININ-STRAIN B (YAMAGATA)
60 MCG / 0.7 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
42fb80a2f0bb8964
Type
Standard
Back to Health Canada Approvals